QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
NASDAQ:CYCC

Cyclacel Pharmaceuticals - CYCC Price Target & Analyst Ratings

$1.09
+0.14 (+14.74%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.95
$1.10
50-Day Range
$0.54
$1.00
52-Week Range
$0.53
$3.99
Volume
159,494 shs
Average Volume
85,401 shs
Market Capitalization
$13.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Cyclacel Pharmaceuticals Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 2 Analyst Ratings

Consensus Analyst Price Target

$10.00
817.43% Upside
High Prediction$10.00
Average Prediction$10.00
Low Prediction$10.00
TypeCurrent
2/2/22 to 2/2/23
1 Month Ago
1/3/22 to 1/3/23
3 Months Ago
11/4/21 to 11/4/22
1 Year Ago
2/2/21 to 2/2/22
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$10.00$10.00$17.00$17.00
Predicted Upside817.43% Upside898.10% Upside475.30% Upside183.81% Upside
Get Cyclacel Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter.


CYCC Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CYCC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Cyclacel Pharmaceuticals Stock vs. The Competition

TypeCyclacel PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.65
2.46
Consensus RatingBuyBuyHold
Predicted Upside817.43% Upside1,296.70% Upside7.34% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/19/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$17.00 ➝ $10.00+1,209.23%
10/3/2022Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Dolliver
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
11/18/2021LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$18.00 ➝ $17.00+264.03%
5/21/2020Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Aschoff
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$24.00+449.20%
(Data available from 2/2/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












CYCC Price Target - Frequently Asked Questions

What is Cyclacel Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for Cyclacel Pharmaceuticals stock is Buy based on the current 2 buy ratings for CYCC. The average twelve-month price prediction for Cyclacel Pharmaceuticals is $10.00 with a high price target of $10.00 and a low price target of $10.00. Learn more on CYCC's analyst rating history.

Do Wall Street analysts like Cyclacel Pharmaceuticals more than its competitors?

Analysts like Cyclacel Pharmaceuticals more than other Medical companies. The consensus rating score for Cyclacel Pharmaceuticals is 3.00 while the average consensus rating score for medical companies is 2.65. Learn more on how CYCC compares to other companies.

Does Cyclacel Pharmaceuticals's stock price have much upside?

According to analysts, Cyclacel Pharmaceuticals's stock has a predicted upside of 898.10% based on their 12-month price targets.

What analysts cover Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals has been rated by Oppenheimer in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:CYCC) was last updated on 2/2/2023 by MarketBeat.com Staff